Quest Diagnostics Inc. vs Abbvie Inc.
DGX vs ABBV — side-by-side comparison from reported financials. DGX leads 5, ABBV leads 6 of 11 comparable metrics.
Quest Diagnostics Inc.
DGX · Healthcare
$230.97+0.07%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | DGX | ABBV |
|---|---|---|
| Price | $230.97 | $276.43 |
| Market cap | $25.5B | $488B |
| Revenue (TTM) | $11.6B | $64.4B |
| Revenue growth | +3.7% | +1.8% |
| Net margin | 9.2% | 9.8% |
| Free cash flow | $1.35B | $18.2B |
| Net cash (debt) | ($4.75B) | ($56.2B) |
| 1-year price return | +27.3% | +19.8% |
| P/E | 24.0 | 77.4 |
| P/E vs own history (cheap-side %) | 5% | 23% |
| Dividend yield | 1.42% | 2.45% |
| Return on equity | 14% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 57,000 | 57,000 |
Full résumé-style profiles: DGX CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.